Organization
Janssen R&D
4 abstracts
Abstract
Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.Org: Gustave Roussy Cancer Center, University of Pennsylvania, National Cancer Center Hospital East, Kashiwa, Japan, Seoul National University Bundang Hospital, Yonsei University College of Medicine,
Abstract
Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone.Org: Institut Curie, Saint Cloud, France, Virginia Cancer Specialists, Columbia University Medical Center, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Providence Cancer Institute,
Abstract
Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Yonsei Cancer Center, Yonsei University Health System, Yonsei University College of Medicine,
Abstract
Generalizable FGFR prediction across tumor types using self supervised learning.Org: Janssen R & D, LLC, Los Angeles, CA, Janssen R&D, Janssen Research & Development,